Results 61 to 70 of about 898,102 (296)
HDAC and HDAC Inhibitor: From Cancer to Cardiovascular Diseases [PDF]
Histone deacetylases (HDACs) are epigenetic regulators that regulate the histone tail, chromatin conformation, protein-DNA interaction, and even transcription. HDACs are also post-transcriptional modifiers that regulate the protein acetylation implicated in several pathophysiologic states.
Yoon, Somy, Eom, Gwang Hyeon
openaire +2 more sources
A novel PLGA/PBAE polymer microparticle platform revolutionizes intermediate‐stage liver cancer treatment by co‐delivering panobinostat and IL‐12 via a single TACE‐like injection. This sustained‐release system overcomes tumor immunosuppression, triggers robust innate and adaptive immune responses, and establishes tertiary lymphoid structures ...
Hongzhe Yu +7 more
wiley +1 more source
Current HDAC Inhibitors in Clinical Trials
Epigenetic modifications in eukaryotic biological pathways can lead to the up- or downregulation of regulatory proteins contributing to disease onset and progression. In the last three decades, histone deacetylases (HDACs) are among the most studied epigenetic targets.
Elisabetta Di Bello +3 more
openaire +4 more sources
Hepatocellular carcinoma (HCC) is a frequent cause of cancer-related death; therefore, more effective anticancer therapies for the treatment of HCC are needed.
楊家榮;鄧哲明 +1 more
core +1 more source
SOX2 upregulates KAT7 in glioma stem cells, where KAT7 deposits H3K14 acetylation at the RAC2 promoter to activate RAC2 transcription. RAC2‐GTP subsequently promotes PAK1/2/3 phosphorylation, increasing tricarboxylic acid cycle flux and mitochondrial respiration to support glioblastoma malignancy.
Jilong Liu +13 more
wiley +1 more source
Improved Synthesis and Structural Reassignment of MC1568: A Class IIa Selective HDAC Inhibitor
An improved synthesis and structural reassignment of the class IIa selective histone deacetylase (HDAC) inhibitor MC1568 are ...
Vidhi Gaur (1845805) +4 more
core +1 more source
A low dose of dexmedetomidine, delivered by ROS‐responsive nanoparticles, preferentially accumulates in the ischemic intestine and restores gut vascular barrier integrity after ischemia/reperfusion injury. This nanoparticle‐based strategy prevents bacterial translocation and liver damage without cardiorespiratory side effects, working through HDAC ...
Hu‐Fei Zhang +10 more
wiley +1 more source
Bifunctional HDAC Therapeutics: One Drug to Rule Them All?
Histone deacetylase (HDAC) enzymes play crucial roles in epigenetic gene expression and are an attractive therapeutic target. Five HDAC inhibitors have been approved for cancer treatment to date, however, clinical applications have been limited due to ...
Joshua P. Smalley +2 more
doaj +1 more source
Rational Combinations Using HDAC Inhibitors [PDF]
Abstract In addition to well-characterized genetic abnormalities that lead to cancer onset and progression, it is now recognized that alterations to the epigenome may also play a significant role in oncogenesis. As a result, epigenetic-modulating agents such as histone deacetylase inhibitors (HDACi) have attracted enormous attention as ...
Bots, Michael, Johnstone, Ricky W.
openaire +2 more sources
In this study we demonstrate that histone deacetylase (HDAC)-inhibitor mediated cell surface expression of the structural different NKG2D-ligands MICA/B and ULBP2 is calcium-dependent.
Hagemann-Jensen, Michael Henrik +3 more
core +1 more source

